---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-002083"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:39:26.062728+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera prelim FY2023 revenue $33.8-34.3M, record high, up ~19% YoY

## Summary
- FY 2023 revenue $33.8M-$34.3M, record high, ~19% growth vs 2022.
- Q4 2023 revenue $10.4M-$10.9M, up ~5% vs Q4 2022.
- Second half 2023 sales grew 34%-37% compared to prior year.
- Preliminary and unaudited; final results expected in March 2024.

## SEC filing metadata
- accession: 0001493152-24-002083
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224002083/0001493152-24-002083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224002083/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-002083
- JSON: https://secwatch.observer/filing/0001493152-24-002083.json
- Plain text: https://secwatch.observer/filing/0001493152-24-002083.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported preliminary financial results for three and twelve months ended December 31, 2023.
  - Period: three and twelve months ended December 31, 2023
  - Result: preliminary results
  source text: On January 11, 2024 Biofrontera Inc. (the "Company") issued a press release announcing its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224002083/0001493152-24-002083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.